X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-beats-quarterly-profit-estimates-alzheimers-drug-sales-jump-2024-04-24/#:~:text=April%2024%20(Reuters)%20%2D%20Biogen,Alzheimer\'s%20disease%20drug%20remained%20sluggish.
https://www.prnewswire.com/news-releases/leqembi-revenue-totaled-jpy-2-83-billion-in-the-first-quarter-2024--302126045.html
https://www.reuters.com/business/healthcare-pharmaceuticals/alzheimers-drug-adoption-us-slowed-by-doctors-skepticism-2024-04-23/
https://www.prnewswire.com/news-releases/bioarctic-and-eisai-sign-research-evaluation-agreement-regarding-ban2802-302122671.html
https://www.biospectrumasia.com/news/25/24098/eisais-antiepileptic-drug-fycompa-injection-formulation-launches-in-japan.html
https://www.fiercebiotech.com/biotech/lilly-alzheimers-med-glides-out-leqembi-slipstream-toward-fda-turbulence-adcomm-request
https://www.prnewswire.com/news-releases/eisai-to-present-data-on-robust-neurology-portfolio-at-the-76th-american-academy-of-neurology-aan-annual-meeting-302114979.html
https://www.biospectrumasia.com/news/25/24059/french-sales-subsidiary-of-japanese-pharma-firm-eisai-divests-rights-of-neurology-drugs-for-56-5-m.html
https://www.fiercepharma.com/pharma/eisai-biogens-injectable-leqembi-delayed-fda-asks-more-data
https://www.prnewswire.com/news-releases/submission-of-leqembi-lecanemab-irmb-sbla-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-to-the-us-fda-completed-302104249.html
Market Place
Share 
